Skip to content
DataLookout
Menu

TORCH-E3NCT07933679

SCRT Combined With CAPOX and PD-1 Antibody Versus LCRT Combined With CAPOX for Early Low-lying Rectal Cancer (TORCH-E3)

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

3 year TME-free survival rate
Timeframe: the proportion of patients who remain alive and have not undergone total mesorectal excision (TME) surgery within three years from the start of treatment.

Secondary (7)

complete response (CR) rate
Organ preservation rate
3 year local recurrence free survival rate
3 year disease free survival rate
3 year overall survival rate
Show 2 moreShow less
3 year Quality of Life
Grade 3-4 adverse effects rate

Arms and interventions

SCRT plus immunochemotherapy groupExperimental

Patients will receive SCRT (25Gy/5Fx, SCRT), followed by 4 cycles of CAPOX and PD-1 antibody, finally receive the TEM or TME surgery or adopt WW option.

LCRT plus chemotherapy groupOther

Patients will receive LCRT (50Gy/25Fx,LCRT, concurrent capecitabine), followed by 2 cycles of CAPOX, finally receive the TEM or TME surgery or adopt WW option.

Radiation: Short-course radiotherapy, Long-course radiation

Drugs: PD-1 antibody (Sintilimab), Oxaliplatin, Capecitabine

Sites

1 site in 1 country

  • Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China